Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms REGOTAS
- 04 Jul 2017 Status changed from recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jan 2017 Planned End Date changed from 30 Jun 2017 to 30 Sep 2016.